Advanced monoclonal antibody discovery
Kymab is a biopharmaceutical company using a proprietary transgenic antibody platform, Kymouse, to discover and develop fully human monoclonal antibody drugs. The technology used to design the Kymouse strains originated from the Wellcome Trust Sanger Institute in Cambridge, UK.
Kymouse HK™ provides an efficient means of generating high affinity fully human monoclonal antibodies against a broad range of drug targets and has been designed to overcome many of the limitations of previous humanised transgenic antibody strains.
Our partnering strategy is designed to provide access to Kymouse HK™ to commercial partners through flexible non-exclusive licensing agreements. Kymab is also keen to work with academic collaborators who wish to access fully human antibodies for research purposes.